Research Reports

Veeda Clinical Research Unlisted Shares

Veeda Clinical Research company logo

Veeda Clinical Research Share Price

DMAT

PUBLIC LIMITED

Price Chart

1W
1M
1Y
MAX

High

₹560

Low

₹467

Return

-7.52%

Veeda Clinical Research Essentials

As of May 09, 2026, Veeda Clinical Research, Unlisted Shares are trading at ₹447.00 per share and face value is ₹2.00/share, with a 52-week high of ₹529.00 and 52-week low of ₹467.00. The minimun lot size is 500 shares, and the shares are traded on .

ISIN

info icon

INE01HQ01026

Face Value

info icon

2

Total Shares

info icon

6,57,77,495

Market Cap

info icon

2,940.25 Cr

Profit After Tax

info icon

0 None

Total Revenue

info icon

0 None

Sector

info icon

Health Care

Sub-sector

info icon

Pharmaceuticals

Category

info icon

Pre IPO

About Veeda Clinical Research

  • Overview: Veeda Clinical Research, a leading CRO in India, has been operating for two decades, providing comprehensive services across various stages of drug development including preclinical, early phase, and late-phase clinical trials, bioanalytical assessment, and drug launch.
  • Technical Expertise: The organization specializes in pharmacokinetics (PK) studies and trials for generic molecules, new chemical entities, large molecules, and biosimilars, with an impressive ISR (Incurred Sample Reanalysis) rate of >95%, surpassing the USFDA recommended rate of 67%.
  • Service Spectrum: Veeda offers bioavailability (BA) & bioequivalence (BE) studies, bioanalytical research, medical writing, pharmacovigilance, preclinical trials, clinical trials (Phase I to Phase III), biosimilars, biopharmaceutics, data science, and post-marketing surveillance.
  • Bioanalytical Research: Developed over 1,000 bioanalytical methods, including 860 generics, 70+ complex generics, 30+ large molecule assays, and 70+ in-house methods.
  • Clinical Trial Expertise: Provides a range of clinical development programs to pharmaceutical, biotech, generic, and medical device companies, ensuring fully ICH-GCP compliant operations, including early phase (Phase I) and late phase (Phase II & III) clinical trials.
  • Biosimilars: Through a joint venture with Ingenuity Biosciences, Veeda offers specialized clinical services including PK antidrug antibodies, neutralizing antibodies, and biomarker assays, as well as characterization and comparability testing.
  • Global Reach: With a significant client base in North America, Europe, and Asia, Veeda generates approximately 70% of its revenue from overseas clients.
  • Facilities: Operates around 7 facilities, each catering to different stages of the drug development cycle, and has a subsidiary, Bioneeds, for preclinical research, providing an operational edge.
  • Clients: Veeda Clinical Research has completed studies for numerous high-profile clients worldwide, including Dr. Reddy’s Laboratories Limited, Mankind Pharma Limited, and Granules India Limited in India; Laboratorios Liconsa, S.A (Chemo) in Europe; Novugen Pharma (Malaysia) SDN. BHD. in Malaysia; Sunshine Lake Pharma Co. Ltd and Ǫilu Pharmaceutical Co., Ltd in China; and Upsher-Smith Laboratories LLC and Osmotica Pharmaceutical US LLC in the USA.

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Veeda Clinical Research Media

News

Articles

Videos

Veeda Clinical Research: CX Partners-led consortium looks to sell majority stake, eyes $600 mn -$650 mn valuation

Veeda Clinical Research: CX Partners-led consortium looks to sell majority stake, eyes $600 mn -$650 mn valuation

28 Apr 2024

Moneycontrol

Veeda Clinical Research buys European CRO Heads for an undisclosed sum

Veeda Clinical Research buys European CRO Heads for an undisclosed sum

25 Mar 2024

Business Standard

CX Partners Backed Veeda Gets SEBI Nod For IPO

CX Partners Backed Veeda Gets SEBI Nod For IPO

27 Dec 2021

VC Circle

Frequently Asked Question (FAQs)

Where can I find the annual report of Veeda Clinical Research Ltd?

The annual report of Veeda Clinical Research Ltd is available in the annual report section.

How to buy Veeda Clinical Research Unlisted Shares?

Please find below the procedure for buying Veeda Clinical Research Unlisted Shares at Planify.
• 1. You confirm booking of Veeda Clinical Research Unlisted Shares with us at a trading price.
• 2. You provide your client master report (ask the broker if not available) along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
• 3. We will provide the bank details.
• 4. You need to transfer funds in that account.
• 5. Payment has to be done in RTGS/NEFT/IMPS CHEQUE TRANSFER. No CASH DEPOSIT.
• 6. Payment has to be done from the same account in which shares are to be credited.
• 7. We will transfer the shares in 24 hours if funds are credited before 2 pm.
Important Note: Please note that the lock-in period for selling Veeda Clinical Research Unlisted Shares is 6 months after listing. Hence you can’t sell Veeda Clinical Research Unlisted Shares which you bought in Pre-IPO for 6 months after its listing. i.e. You can sell it only after 6 months calculated from the listing date.

What is the lock-in period of Veeda Clinical Research Unlisted Shares?

Lock-in period of Veeda Clinical Research Unlisted Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of Veeda Clinical Research Unlisted Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of Veeda Clinical Research Unlisted Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.

See More

Veeda Clinical Research

₹ 447

cartIcon